TRAVERE THERAPEUTICS INC (TVTX)
Sector: Health Care
2026 Annual Meeting Analysis
TRAVERE THERAPEUTICS INC · Meeting: May 19, 2026
Directors FOR
9
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Dr. Baynes is a sitting executive officer (Chief Medical Officer) at a public company, Eikon Therapeutics, and simultaneously serves on four public company boards (Travere, Natera, Nurix, and Aardvark), which exceeds the policy limit of two outside board seats for a sitting public company executive officer.
For Analysis
Dr. Bruhn has served since April 2020, has relevant biopharmaceutical and rare disease experience, meets independence standards, attended all meetings above the 75% threshold, holds two public board seats, and TVTX's 3-year TSR of +44.1% outperforms the peer median by +10.4pp, well below the 65pp trigger threshold.
Mr. Coughlin has served since March 2015, chairs the Audit Committee, holds a CPA and CFO background relevant to financial oversight, meets independence standards, and no TSR, overboarding, or attendance flags apply.
Dr. Dube is the CEO and executive director; TVTX's 3-year TSR of +44.1% outperforms the disclosed peer median by +10.4pp, which is well below the 65pp underperformance threshold required to trigger a vote against, and no other director-specific flags apply.
Mr. Lyons has served as Board Chair since May 2016, brings extensive pharmaceutical industry leadership experience, meets independence standards, has no attendance or overboarding flags, and TVTX's 3-year TSR outperformance versus the peer group is positive.
Mr. Meckler has served since October 2014, has relevant life sciences and corporate finance experience, chairs the Nominating/Corporate Governance Committee, meets independence standards, and no TSR, overboarding, or attendance flags apply.
Mr. Orwin has served since March 2017, has deep commercial and strategic life sciences experience, chairs the Compensation Committee, meets independence standards, and no TSR, overboarding, or attendance flags apply.
Ms. Poole has served since May 2019, brings relevant manufacturing, operations, and rare disease development expertise, meets independence standards, and no TSR, overboarding, or attendance flags apply.
Mr. Squarer has served since April 2017, has extensive commercial and executive leadership experience in pharma, serves on the Audit Committee, meets independence standards, and no TSR, overboarding, or attendance flags apply.
Ms. Williams-Brinkley has served since September 2021, brings healthcare operations and strategic experience, meets independence standards, and no TSR, overboarding, or attendance flags apply.
Nine of ten director nominees receive a FOR vote. Roy Baynes receives an AGAINST vote solely due to overboarding: he is a sitting executive officer (Chief Medical Officer) at a public company, Eikon Therapeutics, and simultaneously holds seats on four public company boards, exceeding the policy's two-outside-board limit for sitting public company executives. All other nominees pass TSR, independence, attendance, and qualification screens. TVTX's 3-year TSR of +44.1% outperforms the disclosed peer median by +10.4pp, well within the 65pp underperformance threshold needed to trigger a vote against any director, so no TSR-based against votes apply to the broader slate.
Say on Pay
✓ FORCEO
Eric Dube, Ph.D.
Total Comp
$8,457,151
Prior Support
N/A
CEO Eric Dube received total compensation of $8,457,151 in 2025, which is within a reasonable range for a CEO of a ~$2.9B commercial-stage biotech company. The pay mix is heavily weighted toward variable compensation — base salary of $854,250 represents only about 10% of total pay, with the remainder consisting of performance-tied stock awards (including performance stock awards that vest only upon clinical or regulatory milestones), time-based stock options, and a cash bonus tied to annual goals, well exceeding the 50-60% variable pay requirement. TVTX's 3-year TSR of +44.1% outperforms the disclosed peer median (+33.7%) by +10.4pp, and the 1-year TSR of +92.2% significantly outpaces the peer median (+29.2%), supporting the conclusion that above-target incentive compensation in 2025 was earned in alignment with strong shareholder returns; the company also maintains a Dodd-Frank clawback policy.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$1,745,458
Non-Audit Fees
$90,600
Non-audit fees (tax compliance and consulting) were $90,600 against audit fees of $1,745,458, representing approximately 5.2% of audit fees — well below the 50% threshold that would raise independence concerns. EY is a Big 4 firm appropriate for Travere's ~$2.9B market cap. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire per policy; this absence is noted as a minor negative but does not change the vote.
Overall Assessment
The 2026 Travere Therapeutics annual meeting presents a largely clean ballot. Nine of ten director nominees receive a FOR vote; Roy Baynes receives an AGAINST due to overboarding as a sitting public company executive holding four outside board seats. The auditor ratification and Say on Pay proposals both pass policy screens and receive FOR votes, supported by low non-audit fees, a heavily variable executive pay structure, and TVTX's strong 3-year and 1-year TSR outperformance versus its disclosed peer group.
Compensation Peer Group
19 companies disclosed in 2026 proxy filing